

Diabetes, Sleep Apnea, Obesity and Cardiovascular Disease: Why not Address them together?

Salim R. Surani

Abstract

Obesity, sleep apnea, diabetes and cardiovascular diseases are some of the most common diseases encountered by the worldwide population, with high social and economic burdens. Significant emphasis has been placed on obtaining blood pressure, body mass index, and placing importance on screening for signs and symptoms pointing towards cardiovascular disease. Symptoms related to sleep, or screening for sleep apnea has been overlooked by cardiac, diabetic, pulmonary and general medicine clinics despite recommendations for screening by several societies. In recent years, there is mounting data where obesity and obstructive sleep apnea sit at the epicenter and its control can lead to improvement and prevention of diabetes and cardiovascular complications. This editorial raises questions as to why obstructive sleep apnea screening should be included as yet another vital sign during patient initial inpatient or outpatient visit.

Obstructive Sleep Apnea

Should obstructive sleep apnea (OSA) screening be included as yet another vital sign during the patient first visit? Obesity and metabolic syndromes are emerging as major public health issues. One point one billion adults population worldwide are overweight, and approximately 312 million of them are obese.¹ Obesity is highly prevalent in United States but the prevalence is increasing in China, Southeast Asia, Middle East and Pacific Island.² The increasing incidence of childhood obesity and its association with the cardiovascular disease is also becoming a major public health concern.^{3,4} The number of individuals inflicted with diabetes worldwide is approximately 285 million, but is expected to increase to 439 million by 2030.⁵ 17 million deaths out of 57 million total worldwide deaths are attributable to cardiovascular disease.⁶ The prevalence of OSA is between 4%–7% and increasing.⁷

Obesity and OSA seem to be an epicenter for most of the chronic disease catastrophe. OSA is one of the most common diseases, with a high incidence and prevalence rate that parallels with increasing obesity globally. OSA can be seen in non-obese patients with craniofacial abnormality and children with enlarged tonsils and adenoids too.^{8–10} The growing prevalence of obesity and the increasing population body mass index has created major public health challenges.¹¹ Obstructive sleep apnea has been independently linked with hypertension, atrial fibrillation, cardiac disease, worsening of diabetes, insulin resistance, peri-operative and postoperative complications and coronary artery disease (CAD), to name the few.^{12–16} In other words, the data links obstructive sleep apnea to a majority of chronic illnesses. In addition to the illness, untreated OSA increases the health care utilization, impairs work place efficiency, occupational injuries and increase healthcare utilization leading to billions of dollars in economic burden worldwide.¹⁷ OSA if recognized can be adequately

treated by an armamentarium of several different treatment modalities. Despite that 85% of the patients with clinically significant and treatable OSA have never been diagnosed, in other word the data has not made to the bedside.¹⁸

OSA involves partial or complete collapse of the upper airway, despite respiratory efforts alternating with normal breathing. It affects 4%–7% of the population⁷ and its prevalence in patients with cardiovascular disease is very high. Apnea is defined as a decline in peak signal excursion by $\geq 90\%$ of their pre-event baseline for ≥ 10 s. Hypopnea is defined as a drop in the signal excursion by $\geq 30\%$ of their pre-event baseline for $\geq 10\%$ and $\geq 3\%$ arterial oxygen desaturation or accompanied by an arousal.¹⁹ OSA severity is based on Apnea-hypopnea index/h (AHI/h) It can be divided into mild OSA (AHI 5–15/h), Moderate OSA (AHI 15–30/h), and severe OSA (AHI > 30 /h). The pathophysiology of obesity and OSA is intimately linked together. Obesity is a major risk factor for OSA. In obese patients there is an enlargement of soft tissue structures in the upper airway, leading to airway obstruction, especially during rapid eye movement sleep when there is atonia. In addition to obesity, there is an increase in fat deposition under the mandible, macroglossia, and palate, which can then lead to narrowing of airway and lead to apnea and hypopnea.^{20,21} Obesity has been linked as the central and reversible cardiovascular risk factor that positively influences OSA, diabetes mellitus (DM), metabolic syndrome, hypertension, and lipid metabolism.¹⁷ Children are not immune to the obesity, as the prevalence of obesity among children aged 2–5 is 10% and 6–19 years old is 15%.²²

OSA affects an estimated 15 million adult Americans, especially patients with hypertension, Atrial fibrillation (A-Fib), CAD, and congestive heart failure (CHF) where it is pervasive and levels are very high.²³ Additionally, OSA treatment has also been shown to improve atrial fibrillation incidence, coronary stent relogging, and improvement of CHF and improvement in blood glucose and insulin resistance.^{24–29} Recent evidence directly links OSA and obesity to CAD, heart failure, cardiomyopathy, A- Fib and DM and they are

Salim R Surani, Department of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Texas A and M University, Aransas Pass, TX 78336, USA. Reprinted World J Diabetes 2014; 5(3): 381




Figure 1. Showing the relationship of obstructive sleep apnea to cardiovascular diseases, diabetes, metabolic syndrome and obesity. CAD: Coronary artery disease; HTN: Hypertension; CVA: Cerebrovascular accident; DM: Diabetes mellitus; OSA: Obstructive sleep apnea.

interrelated too as shown in **Figure 1**. The rise of obesity and DM has been an increased threat to the health of the global population, which has been catalyzed and compounded by the increased occurrence of OSA. In a recent study by Sleep AHEAD Research Group, OSA (AHI ≥ 5) was found to be in 86% of the population, whereas the pervasiveness of all forms of cardiovascular disease was 14%.³⁰ On the other hand, individuals who have DM and metabolic syndrome have an increased risk of cardiovascular disease and stroke.³¹

The screening for OSA for commercial drivers has been suggested by several societies as American College of Chest Physician, American College of Occupational and Environmental Medicine, and National Sleep Foundation. The International Diabetes federation also recommends screening patients for possible OSA.³² This screening among the commercial drivers has been successfully implemented, on the other hand, peri-operative screening has been suggested but not implemented in majority of the hospitals despite the availability of simple screening tools as STOP-Bang Questionnaire,³³ Berlin Questionnaire,³⁴ neck size, airway, morbidity, Epworth Sleepiness Score, snoring (NAMES) criteria, all with the sensitivity ranging from 80% to 86%.³⁵

This data has been in literature now for several years, indicating the associations of OSA with almost any disease as glaucoma, end stage renal disease, chronic obstructive pulmonary disease, polycystic ovarian syndrome, metabolic syndrome, cardiovascular disease, stroke, depression, obesity and DM. Moreover, the treatment has led to improvements in the underlying condition.³⁶⁻³⁸ The screening test carries high sensitivity, but also has a low specificity. This can result in a plethora of false positive diagnosis and may increase the health care cost. There is high relationship between OSA, hypertension, cerebrovascular disease, CAD and A-Fib. Early diagnosis and treatment of OSA will help in preventing the increase morbidity and mortality associated with those conditions. Studies have shown the improvement in ejection fraction, carotid intimal thickening and benefits in coronary artery disease, maintenance of sinus rhythm from A-Fib after

cardioversion and improvement in insulin resistance. Moreover untreated OSA is also associated with increased risk of death.³⁹⁻⁴⁶ The question arises, if it is the prime time to push for OSA screening for every patient walking in outpatient clinic or hospital? Or do we have to adjust the cutoff of points of our screening test so we can compromise with a decrease in sensitivity to have better specificity to avoid excess healthcare cost as a result of high false positive tests. It is the opinion of the author that Stop-Bang questionnaire, Berlin or NAMES questionnaire can be utilized as the screening tool. In the presence of symptoms, patient should undergo formal sleep study with home sleep study or overnight in lab polysomnography.³³⁻³⁵ Regardless, one thing is clear: that every physician, nurse and midlevel provider needs to educate patients on risk prevention and education regarding the causes, signs and symptoms of diabetes, sleep apnea, obesity prevention and cardiovascular disease prevention. It is about time that health care providers take the responsibility of preventative education of such diseases as a package rather than fragmentation of education of diabetes in diabetic clinics, sleep apnea in sleep clinics, and cardiovascular disease in heart clinics, as these diseases are interrelated. I will leave the debate open as to if it is about time to push for screening of OSA as one of the vital signs on every patient initial visit.

References

- Hossain P, Kowar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. *N Engl J Med* 2007; 356: 213–215 [PMID: 17229948 DOI: 10.1056/NEJMp068177]
- Haidar YM, Cosman BC. Obesity epidemiology. *Clin Colon Rectal Surg* 2011; 24: 205–210 [PMID: 23204935 DOI: 10.1055/s-0031-1295684]
- Nguyen JV, Robbins JM, Houck KL, Nobis EA, Inman KA, Khan KS, Robbins SW. Severe obesity and high blood pressure among children, Philadelphia health centers, 2010. *J Prim Care Community Health* 2014; 5: 152–155 [PMID: 24327594]
- Luca AC, Iordache C. Obesity—a risk factor for cardiovascular diseases. *Rev Med Chir Soc Med Nat Iasi* 2013; 117: 65–71 [PMID: 24505894]
- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010; 87: 4–14 [PMID: 19896746 DOI: 10.1016/j.diabres.2009.10.007]
- Bovet PFF. Cardiovascular disease and the changing face of global public health: a focus on low and middle income countries. *Public Health Review* 2012; 33: 397–415
- Punjabi NM. The epidemiology of adult obstructive sleep apnea. *Proc Am Thorac Soc* 2008; 5: 136–143 [PMID: 18250205 DOI: 10.1513/pats.200709-155MG]
- Willington AJ, Ramsden JD. Adenotonsillectomy for the management of obstructive sleep apnea in children with congenital craniosynostosis syndromes. *J Craniofac Surg* 2012; 23: 1020–1022 [PMID: 22777462 DOI: 10.1097/SCS.0b013e31824e6cf8]
- Sutherland K, Lee RW, Cistulli PA. Obesity and craniofacial structure as risk factors for obstructive sleep apnea: impact of ethnicity. *Respirology* 2012; 17: 213–222 [PMID: 21992683 DOI: 10.1111/j.1440-1843.2011.02082.x]
- Aihara K, Oga T, Harada Y, Chihara Y, Handa T, Tanizawa K, Watanabe K, Hitomi T, Tsuboi T, Mishima M, Chin K. Analysis of anatomical and functional determinants of obstructive sleep apnea. *Sleep Breath* 2012; 16: 473–481 [PMID: 21573913 DOI: 10.1007/s11325-011-0528-7]
- Zalesin KC, Franklin BA, Miller WM, Peterson ED, Mc-Cullough PA. Impact of obesity on cardiovascular disease. *Med Clin North Am* 2011; 95: 919–937 [PMID: 21855700 DOI: 10.1016/j.mcna.2011.06.005]
- Goyal SK, Sharma A. Atrial fibrillation in obstructive sleep apnea. *World J Cardiol* 2013; 5: 157–163 [PMID: 23802045 DOI: 10.4330/wjc.v5.i6.157]
- Bonsignore MR, Borel AL, Machan E, Grunstein R. Sleep apnea and metabolic dysfunction. *Eur Respir Rev* 2013; 22: 353–364 [PMID: 23997062 DOI: 10.1183/09059180.00003413]

14. Hamilton GS, Naughton MT. Impact of obstructive sleep apnea on diabetes and cardiovascular disease. *Med J Aust* 2013; 199: S27–S30 [PMID: 24138362 DOI: 10.5694/mja13.10579]
15. Tahrani AA, Ali A, Stevens MJ. Obstructive sleep apnea and diabetes: an update. *Curr Opin Pulm Med* 2013; 19: 631–638 [PMID: 24048079 DOI: 10.1097/MCP.0b013e3283659 da5]
16. Nepomnayshy D, Hesham W, Erickson B, MacDonald J, Iorio R, Brams D. Sleep apnea: is routine preoperative screening necessary? *Obes Surg* 2013; 23: 287–291 [PMID: 23104390 DOI: 10.1007/s11695-012-0806-x]
17. AlGhanim N, Comondore VR, Fleetham J, Marra CA, Ayas NT. The economic impact of obstructive sleep apnea. *Lung* 2008; 186: 7–12 [PMID: 18066623 DOI: 10.1007/s00408-007-90 55-5]
18. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). *Circulation* 2008; 118: 1080–1111 [PMID: 18725495 DOI: 10.1161/CIRCULATIONAHA.107.189420]
19. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SF, Redline S, Strohl KP, Davidson Ward SL, Tangredi MM. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med* 2012; 8: 597–619 [PMID: 23066376]
20. Schwab RJ, Pasirstein M, Pierson R, Mackley A, Hachadorian R, Arens R, Maislin G, Pack AI. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. *Am J Respir Crit Care Med* 2003; 168: 522–530 [PMID: 12746251 DOI: 10.1164/rccm.200208-866OC]
21. Horner RL, Shea SA, McIvor J, Guz A. Pharyngeal size and shape during wakefulness and sleep in patients with obstructive sleep apnea. *Q J Med* 1989; 72: 719–735 [PMID: 2602554]
22. Smith I, Lasserson TJ. Pressure modification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnea. *Cochrane Database Syst Rev* 2009; (4): CD003531 [PMID: 19821310 DOI: 10.1002/14651858]
23. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. *J Am Coll Cardiol* 2008; 52: 686–717 [PMID: 18702977 DOI: 10.1016/j.jacc.2008.05.002]
24. Diaz-Meleán CM, Somers VK, Rodriguez-Escudero JP, Singh P, Sochor O, Llano EM, Lopez-Jimenez F. Mechanisms of adverse cardiometabolic consequences of obesity. *Curr Atheroscler Rep* 2013; 15: 364 [PMID: 24048571 DOI: 10.1007/s11883-013-0364-2]
25. Mansukhani MP, Calvin AD, Kolla BP, Brown RD, Lipford MC, Somers VK, Caples SM. The association between atrial fibrillation and stroke in patients with obstructive sleep apnea: a population-based case-control study. *Sleep Med* 2013; 14: 243–246 [PMID: 23340087 DOI: 10.1016/j.sleep.2012.08.021]
26. Kourouklis SP, Vagiakis E, Paraskevidis IA, Farmakis D, Kostikas K, Parissis JT, Katsivas A, Kremastinos DT, Anastasiou-Nana M, Filippatos G. Effective sleep apnea treatment improves cardiac function in patients with chronic heart failure. *Int J Cardiol* 2013; 168: 157–162 [PMID: 23041002 DOI: 10.1016/j.ijcard.2012.09.101]
27. Bopparaju S, Surani S. Sleep and diabetes. *Int J Endocrinol* 2010; 2010: 759509 [DOI: 10.1155/2010/759509]
28. Surani S, Subramanian S. Effect of continuous positive airway pressure therapy on glucose control. *World J Diabetes* 2012; 3: 65–70 [PMID: 22532885 DOI: 10.4239/wjd.v3.i4.65]
29. Surani S. Are diabetic patients being screened for sleep related breathing disorder? *World J Diabetes* 2013; 4: 162–164 [PMID: 24147199]
30. Rice TB, Foster GD, Sanders MH, Unruh M, Reboussin D, Kuna ST, Millman R, Zammit G, Wing RR, Wadden TA, Kelley D, Pi-Sunyer X, Newman AB. The relationship between obstructive sleep apnea and self-reported stroke or coronary heart disease in overweight and obese adults with type 2 diabetes mellitus. *Sleep* 2012; 35: 1293–1298 [PMID: 22942508]
31. Ramar K, Surani S. The relationship between sleep disorders and stroke. *Postgrad Med* 2010; 122: 145–153 [PMID: 21084791 DOI: 10.3810/pgm.2010.11.2232]
32. Shaw JE, Punjabi NM, Wilding JP, Alberti KG, Zimmet PZ. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. *Diabetes Res Clin Pract* 2008; 81: 2–12 [PMID: 18544448 DOI: 10.1016/j.diabres.2008.04.025]
33. Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, Khajehdehi A, Shapiro CM. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology* 2008; 108: 812–821 [PMID: 18431116 DOI: 10.1097/ALN.0b013e31816d83e4]
34. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann Intern Med* 1999; 131: 485–491 [PMID: 10507956 DOI: 10.7326/0003-4819-131-7-199910050-0 0002]
35. Subramanian S, Hesselbacher SE, Aguilar R, Surani SR. The NAMES assessment: a novel combined-modality screening tool for obstructive sleep apnea. *Sleep Breath* 2011; 15: 819–826 [PMID: 21076972 DOI: 10.1007/s11325-010-0443-3]
36. Subramanian S, Guntupalli B, Murugan T, Bopparaju S, Chanamolu S, Casturi L, Surani S. Gender and ethnic differences in prevalence of self-reported insomnia among patients with obstructive sleep apnea. *Sleep Breath* 2011; 15: 711–715 [PMID: 20953842 DOI: 10.1007/s11325-010-0426-4]
37. Subramanian S, Desai A, Joshupura M, Surani S. Practice patterns of screening for sleep apnea in physicians treating PCOS patients. *Sleep Breath* 2007; 11: 233–237 [PMID: 17541663 DOI: 10.1007/s11325-007-0120-3]
38. Lee R, McNicholas WT. Obstructive sleep apnea in chronic obstructive pulmonary disease patients. *Curr Opin Pulm Med* 2011; 17: 79–83 [PMID: 21169840 DOI: 10.1097/MCP.0b013e32834317bb]
39. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. *Am J Respir Crit Care Med* 2005; 172: 613–618 [PMID: 15901608 DOI: 10.1164/rccm.200503-340OC]
40. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. *Am J Respir Crit Care Med* 2007; 176: 706–712 [PMID: 17556718 DOI: 10.1164/rccm.200703-500OC]
41. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med* 2005; 353: 2034–2041 [PMID: 16282178 DOI: 10.1056/NEJMoa043104 [published]]
42. Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, Nieto FJ, Stubbs R, Hla KM. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep* 2008; 31: 1071–1078 [PMID: 18714778]
43. Moore T, Rabben T, Wiklund U, Franklin KA, Eriksson P. Sleep-disordered breathing in men with coronary artery disease. *Chest* 1996; 109: 659–663 [PMID: 8617073 DOI: 10.1378/chest.109.3.659]
44. Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. *Am J Respir Crit Care Med* 2004; 169: 348–353 [PMID: 14551167 DOI: 10.1164/rccm.200306-767OC]
45. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, Malouf JF, Ammash NM, Friedman PA, Somers VK. Association of atrial fibrillation and obstructive sleep apnea. *Circulation* 2004; 110: 364–367 [PMID: 15249509 DOI: 10.1161/01.CIR.0000136587.68725.8E]
46. Cassar A, Morgenthaler TI, Lennon RJ, Rihal CS, Lerman A. Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention. *J Am Coll Cardiol* 2007; 50: 1310–1314 [PMID: 17903628 DOI: 10.1016/j.jacc.2007.06.028]